（文章来源：证券日报） 证券日报网讯 2月11日，第一医药在互动平台回答投资者提问时表示，为响应商务部等9部门《关于促 进药品零售行业高质量发展的意见》丰富健康服务、提升健康服务体验号召，回应上海市扩大服务消费 倡议，打破传统药店刻板印象、贴合年轻人主动健康消费与情绪价值需求，第一医药"氛子药局"由青年 团队主导设计，落子上海衡复风貌区，打造融合健康茶饮、微醺社交、药妆实验室等多个场景的复合型 健康空间，重构人货场，力求实现品牌从"药品销售"向"健康服务"的转型升级，为都市Z世代带来全新 健康消费体验，让老字号的专业底蕴与当代健康需求同频共振，为品牌注入持久活力。 ...

（记者 王瀚黎） 每经头条（nbdtoutiao）——男子街头逃亡、剑客山间打斗……电影级中国视频大模型被称"地表最 强"，几十个提示字生成15秒视频可商业交付，影视股大涨！记者亲测 每经AI快讯，第一医药2月11日晚间发布公告称，公司第十一届第八次董事会临时会议于2026年2月11日 以通讯方式召开。会议审议了《关于2026年度日常经营性关联交易预计的议案》等文件。 ...

1、董事会表决情况和关联董事回避情况 上海第一医药股份有限公司（以下简称"公司"）于 2026 年 2 月 11 日召开第十 一届董事会第八次（临时）会议，审议通过了《关于 2026 年度日常经营性关联交易预 计的议案》，公司将于 2026 年度与百联集团有限公司（以下简称"百联集团"）及下 属企业发生日常经营性关联交易，根据《上海证券交易所股票上市规则》的有关规定， 公司关联董事张海波先生、姚军先生、周昱先生、李劲彪先生、张睿女士、胡良玉先 生已按规定回避表决，该议案获其余三位非关联董事全票表决通过。 证券代码：600833 证券简称：第一医药 公告编号：临 2026-005 上海第一医药股份有限公司 关于 2026 年度日常经营性关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 重要内容提示： 日常经营性关联交易对上市公司的影响：本次预计的 2026 年度日常经营性关 联交易系公司正常生产经营需要，关联交易定价公允，不存在损害上市公司利益的情 形，不会对公司财务状况、经营成果产生不利影响；在公司同类业务 ...

证券代码：600833 证券简称：第一医药 公告编号：临 2026-004 上海第一医药股份有限公司 第十一届董事会第八次（临时）会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 重要内容提示：本次董事会不存在否决议案，没有董事投反对/弃权票。 上海第一医药股份有限公司（以下简称"公司"）第十一届董事会第八次（临时） 会议于 2026 年 2 月 6 日以邮件方式通知，于 2026 年 2 月 11 日以通讯方式召开。本次 会议由董事长张海波先生召集并主持。本次会议应参加表决董事为 9 名，委托表决 0 名， 实际参加表决董事 9 名。会议的召开符合有关法律、行政法规、部门规章、规范性文件 和《公司章程》的规定，会议形成的决议合法、有效。 根据会议议程，本次会议审议通过以下事项： 一、公司《关于 2026 年度日常经营性关联交易预计的议案》 具体内容详见同日公告于上海证券交易所网站(http://www.sse.com.cn)的《关于 2026 年度日常经营性关联交易预计的公告》(公告编号：临 2026-005) ...

Core Viewpoint - The independent director system for listed companies in China is undergoing a significant transformation, with new regulations aimed at enhancing shareholder representation and governance structures [1][2]. Group 1: Regulatory Changes - The "Management Measures for Independent Directors of Listed Companies" was officially introduced in August 2023, allowing investor protection agencies to publicly solicit shareholder rights and nominate independent directors [1][2]. - This regulatory change aims to amplify the voices of minority shareholders, particularly those who have historically been silent [1]. Group 2: Practical Implementation - The China Securities Investor Services Center has successfully transitioned the new system from concept to practice, with five successful independent director nominations planned from 2024 to 2026 across various companies and ownership structures [1][3]. - The nomination process has evolved to include "joint action" strategies, expanding the backgrounds of independent directors from industry experience to accounting expertise [1][4]. Group 3: Challenges and Participation - Despite a high approval rate of over 99% for the five nominations, actual participation from investors remains limited, with the highest number of participants in a single case being only 17 [2][9]. - The low engagement reflects a "free-rider" mentality among minority shareholders, indicating a need for improved investor education and participation mechanisms [2][9]. Group 4: Governance Impact - The involvement of the China Securities Investor Services Center is seen as a way to internalize external market supervision, enhancing the independence and representativeness of independent directors [5][6]. - The successful nominations have begun to demonstrate a potential shift in corporate governance, allowing for a more balanced representation of shareholder interests within company boards [4][6]. Group 5: Future Directions - The center aims to continue refining the independent director nomination process while addressing practical challenges such as the 1% shareholding requirement for proposal submissions [8][9]. - Experts suggest that regulatory adjustments may be necessary to facilitate the nomination process and encourage broader participation from minority shareholders [8][9].

Core Insights - The independent director system for listed companies in China is undergoing a significant transformation, with the introduction of the "Management Measures for Independent Directors of Listed Companies" in August 2023, which allows investor protection agencies to publicly solicit shareholder rights and nominate independent directors [1][2] Group 1: Key Developments - The new regulations aim to enhance the representation of minority shareholders, particularly those who have been historically silent [1] - The China Securities Investor Services Center has successfully implemented this system in five cases over a year and a half, covering various ownership structures and regions [1][4] - The evolution of the nomination process has shown a clear trend towards "joint action" and an expansion of the backgrounds of independent directors from industry experience to accounting expertise [2][4] Group 2: Challenges and Responses - Despite a high approval rate of over 99% for the shareholder meetings regarding the nominated independent directors, the actual participation of investors in the solicitation process remains limited, highlighting the ongoing issue of minority shareholders' "free-riding" mentality [2][10] - The operational challenges faced by the China Securities Investor Services Center include the difficulty in uniting shareholders who hold more than 1% of shares to exercise their voting rights [9][10] - Recommendations have been made to improve investor participation through education and the establishment of efficient online authorization systems [10] Group 3: Governance Implications - The involvement of the China Securities Investor Services Center in nominating independent directors represents a shift from external oversight to internal participation in corporate governance [7][8] - The selection of independent directors has focused on their professional qualifications and experience, which is expected to enhance the effectiveness of corporate governance [5][8] - The successful nomination of independent directors is seen as a step towards empowering minority shareholders and improving the balance of power within corporate boards [7][8]

Core Insights - The pharmaceutical distribution industry is undergoing significant structural changes driven by the Health China strategy and evolving consumer demands [1] - Shanghai First Pharmaceutical Co., Ltd. is actively innovating by centering on user needs and reforming its business model, exemplified by the launch of "Fenzi Pharmacy" [1] Group 1: Business Model Innovation - "Fenzi Pharmacy" redefines the role of pharmacies from merely selling medications to promoting a healthy lifestyle, catering to new consumer experiences in Shanghai [2] - The pharmacy integrates professional medical services with youthful lifestyle elements, offering unique products like traditional Chinese medicine-based beverages and a beauty lab [2] - The initiative reflects the company's understanding of Gen Z's health consumption needs, showcasing a shift towards becoming a "pharmaceutical and health service provider" [2] Group 2: Operational Support and Infrastructure - The success of "Fenzi Pharmacy" is part of a broader transformation strategy, focusing on refined operations and expanding service networks to cover diverse customer needs [3] - The company has achieved significant coverage with its "Five New Cities" initiative, enhancing convenience for consumers through a variety of pharmacy formats [3] - The establishment of a pet-friendly pharmacy and a health town offering comprehensive services illustrates the company's commitment to a holistic health service network [3] Group 3: Supply Chain and Digitalization - The company is enhancing its supply chain and digital capabilities, optimizing procurement costs and introducing strategic partnerships to improve product flow [4] - A membership chronic disease management system has been implemented, with over 103,000 members registered by mid-2025, supporting refined operational strategies [4] - The construction of a modern intelligent logistics center aims to improve delivery efficiency and accuracy, laying a solid foundation for multi-channel business expansion [4] Group 4: Expansion into Health Services - The company is exploring new growth avenues in the health services sector, including online business enhancements and cross-border sales of health products [5] - Initiatives such as establishing a traditional Chinese medicine decoction service center address patient needs and open new business opportunities [5] - The overall strategy focuses on integrating offline and online services, reinforcing the company's commitment to health and wellness in the evolving market landscape [5]

Group 1 - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between 41.5 million and 62 million yuan, representing a decrease of 10.10613 million to 12.15613 million yuan compared to the previous year, which is a year-on-year decrease of 61.98% to 74.55% [2][6] - The company anticipates a net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, to be between 4.9 million and 7.3 million yuan, with a potential decrease of 197.4 thousand yuan to an increase of 42.6 thousand yuan compared to the previous year, reflecting a year-on-year change of -28.72% to +6.20% [2][6] - The decrease in net profit is primarily attributed to the absence of compensation income from property expropriation that was present in the previous year [10] Group 2 - The company plans to use idle self-owned funds for entrusted wealth management, with a total amount not exceeding 300 million yuan, to improve the efficiency of fund utilization while ensuring normal operational liquidity [17][30] - The investment will focus on fixed-income products with a risk level of R2 or below, and the entrusted wealth management will be conducted with financial institutions that do not have a related party relationship with the company [19][30] - The board of directors has approved the wealth management plan, which will be effective until December 31, 2026, allowing for rolling use of the fund amount within the specified limit [20][30]

Group 1 - The company, First Pharmaceutical, held a temporary board meeting on January 16, 2026, via communication methods to discuss the proposal for using idle self-owned funds for entrusted financial management [1] Group 2 - The silver market has seen a significant increase, with prices rising over 80% in the last 50 days, indicating a level of speculation that surpasses that of gold [1] - Historically, the explosive growth in silver prices often signals that the precious metals bull market is reaching its peak, raising questions about the current market dynamics [1]

证券代码：600833 证券简称：第一医药 公告编号：临 2026-001 上海第一医药股份有限公司（以下简称"公司"）第十一届董事会第七次（临时） 会议于 2026 年 1 月 11 日以邮件方式通知，于 2026 年 1 月 16 日以通讯方式召开。本次 会议由董事长张海波先生召集并主持。本次会议应参加表决董事为 9 名，委托表决 0 名， 实际参加表决董事 9 名。会议的召开符合有关法律、行政法规、部门规章、规范性文件 和《公司章程》的规定，会议形成的决议合法、有效。 根据会议议程，本次会议审议通过以下事项： 一、公司《关于使用闲置自有资金进行委托理财的议案》 为提高公司自有资金使用效率，在做好日常资金调配、保证正常生产经营所需资金 不受影响的基础上，在严格控制风险和充分信息披露的前提下，公司结合自身资金状况， 拟使用闲置自有资金进行委托理财，在有效期内参与风险等级为 R2 及以下固收类理财 产品的认购，总额度控制在 30,000 万元（含 30,000 万元）以内，决议有效期为自第十 一届董事会第七次（临时）会议审议通过之日起至 2026 年 12 月 31 日止。有效期内， 该资金额度可滚动使用。本 ...